Mutations of Cx43 that affect B cell spreading in response to BCR signaling
Letitia Falk,
May Dang-Lawson,
José Luis Vega,
Farnaz Pournia,
Kate Choi,
Caren Jang,
Christian C. Naus,
Linda Matsuuchi
Affiliations
Letitia Falk
CELL and I-cubed (I3) Research Groups, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
May Dang-Lawson
CELL and I-cubed (I3) Research Groups, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
José Luis Vega
Department of Physiology, Pontificia Universidad de postal codes for Chile are in the Author queries table Católica de Chile, 8330025 Santiago, Chile
Farnaz Pournia
CELL and I-cubed (I3) Research Groups, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
Kate Choi
CELL and I-cubed (I3) Research Groups, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
Caren Jang
CELL and I-cubed (I3) Research Groups, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
Christian C. Naus
Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
Linda Matsuuchi
CELL and I-cubed (I3) Research Groups, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
The gap junction (GJ) protein connexin 43 (Cx43) is both necessary and sufficient for B cell receptor (BCR)-mediated cell spreading. To address how Cx43 mediates this effect, we blocked its function genetically, by expressing mutants of Cx43, and pharmacologically, by using chemical inhibitors. While various point mutations of Cx43 inhibited B cell spreading, treatment with channel blocking drugs did not, suggesting that this response was independent of channel function. The critical region of Cx43 appears to be the cytoplasmic carboxyl-terminal (CT) domain, which has previously been shown to be important for B cell spreading. Consistent with this, mutations of either tyrosine 247 or 265 found in the CT were sufficient to inhibit spreading. Thus Cx43 may influence B cell spreading by mechanisms requiring protein binding to, or modification of, these sites in the CT tail.